Skip to main content

Table 2 Baseline demographic and clinical characteristics of study subjects depending on reinfection

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

 

EBMT

MEA

Variable category

Total (59, 100%)

Reinfected group (7, 11.9%)

Continuously eradicated group (52, 88.1%)

p-value*

Total (116, 100%)

Reinfected group (19, 16.4%)

Continuously eradicated group (97, 83.6%)

p-value*

Gender

(N = 59)

(n = 7)

(n = 52)

 

(N = 116)

(n = 19)

(n = 97)

 

  Male

(35, 59.3%)

(4, 57.1%)

(31, 59.6%)

0.816

(69, 59.5%)

(12, 63.2%)

(57, 58.8%)

0.353

  Female

(24, 40.7%)

(3, 42.9%)

(21, 40.4%)

 

(47, 40.5%)

(7, 36.8%)

(40, 41.2%)

 

Age (mean ± SD)

(N = 59)

(n = 7)

(n = 52)

 

(N = 116)

(n = 19)

(n = 97)

 

(56.1 ± 9.3)

(59.9 ± 9.8)

(55.6 ± 9.2)

(56.8 ± 9.5)

(56.7 ± 9.4)

(56.8 ± 9.6)

  20-29

(1, 1.7%)

(0, 0.0%)

(1, 1.9%)

0.306

(1, 0.9%)

(0, 0.0%)

(1, 1.0%)

0.479

  30-39

(1, 1.7%)

(0, 0.0%)

(1, 1.9%)

 

(3, 2.6%)

(0, 0.0%)

(3, 3.1%)

 

  40-49

(13, 22.0%)

(2, 22.2%)

(11, 21.2%)

 

(21, 18.1%)

(6, 31.6%)

(15, 15.5%)

 

  50-59

(21, 35.6%)

(1, 14.3%)

(20, 38.5%)

 

(40, 34.5%)

(5, 26.3%)

(35, 36.1%)

 

  60-69

(20, 33.9%)

(3, 42.9%)

(17, 32.7%)

 

(42, 36.2%)

(6, 31.6%)

(36, 37.1%)

 

  70-79

(3, 5.1%)

(1, 14.3%)

(2, 3.8%)

 

(8, 10.5%)

(2, 10.5%)

(6, 6.2%)

 

  80-89

(0, 0.0%)

(0, 0.0%)

(0, 0.0%)

 

(1, 0.6%)

(0, 0.0%)

(1, 1.0%)

 

Clinical diagnosis

(N = 59)

(n = 7)

(n = 52)

 

(N = 116)

(n = 19)

(n = 97)

 

  Early gastric cancer

(11, 18.6%)

(0, 0.0%)

(11, 21.2%)

0.198

(29, 25.0%)

(7, 36.8%)

(22, 22.7%)

0.77

  Dysplasia

(3, 5.1%)

(1, 14.3%)

(2, 3.8%)

 

(16, 13.8%)

(3, 15.8%)

(13, 13.4%)

 

  Peptic ulcer disease

(17, 28.8%)

(4, 57.1%)

(13, 25.0%)

 

(17, 14.7%)

(3, 15.8%)

(14, 14.4%)

 

  Chronic gastritis

(28, 47.5%)

(2, 28.6%)

(26, 50.0%)

 

(54, 46.6%)

(6, 31.6%)

(48, 49.5%)

 

Histological AG in either antrum or body

(N = 37)

(n =6)

(n = 31)

 

(N = 79)

(n = 14)

(n = 65)

 

  Yes

(21, 56.8%)

(5, 83.3%)

(16, 51.6%)

0.113

(46, 58.2%)

(9, 64.3%)

(37, 56.9%)

0.575

  No

(16, 43.2%)

(1, 16.7%)

(15, 48.4%)

 

(33, 41.8%)

(5, 35.7%)

(28, 43.1%)

 

Histological IM in either antrum or body

(N = 47)

(n = 6)

(n = 41)

 

(N = 97)

(n = 15)

(n = 82)

 

  Yes

(23, 48.9%)

(4, 66.7%)

(21, 51.2%)

0.193

(61, 62.9%)

(8, 53.3%)

(53, 64.6%)

0.52

  No

(24, 51.1%)

(2, 33.3%)

(20, 48.8%)

 

(36, 37.1%)

(7, 46.7%)

(29, 35.4%)

 
  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis; IM, intestinal metaplasia.
  2. All of early gastric cancer patients were cured by endoscopic submucosal dissection.
  3. * P-value for Log-rank test.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us